10x Genomics, Inc. TXG License and royalty revenue — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by 10x Genomics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: 10x Genomics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about 10x Genomics, Inc.'s license and royalty revenue — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 10x Genomics, Inc.'s license and royalty revenue — revenue?
- 10x Genomics, Inc. (TXG) reported license and royalty revenue — revenue of $947K in Q1 2026.
- How has 10x Genomics, Inc.'s license and royalty revenue — revenue changed year-over-year?
- 10x Genomics, Inc.'s license and royalty revenue — revenue decreased by 94.4% year-over-year, from $17.06M to $947K.
- What does license and royalty revenue — revenue mean?
- This metric represents the revenue generated from granting third parties the right to use the company's intellectual property, patents, or proprietary technologies. It reflects the monetization of the company's research and development efforts through royalty payments or licensing fees rather than direct product sales. Growth in this segment indicates successful commercialization of the company's technology portfolio through strategic partnerships and intellectual property enforcement.